EE04581B1 - a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis - Google Patents

a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Info

Publication number
EE04581B1
EE04581B1 EEP200000685A EEP200000685A EE04581B1 EE 04581 B1 EE04581 B1 EE 04581B1 EE P200000685 A EEP200000685 A EE P200000685A EE P200000685 A EEP200000685 A EE P200000685A EE 04581 B1 EE04581 B1 EE 04581B1
Authority
EE
Estonia
Prior art keywords
alpha
inhibitors
integrin receptor
beta
treatment
Prior art date
Application number
EEP200000685A
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town National Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital
Publication of EE200000685A publication Critical patent/EE200000685A/et
Publication of EE04581B1 publication Critical patent/EE04581B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200000685A 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis EE04581B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
EE200000685A EE200000685A (et) 2002-04-15
EE04581B1 true EE04581B1 (et) 2006-02-15

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000685A EE04581B1 (et) 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Country Status (21)

Country Link
EP (1) EP1079843B1 (et)
JP (1) JP2002516287A (et)
CN (1) CN1187084C (et)
AT (1) ATE359804T1 (et)
BR (1) BR9911067A (et)
CA (1) CA2329757C (et)
CZ (1) CZ296262B6 (et)
DE (1) DE69935853T2 (et)
DK (1) DK1079843T3 (et)
EA (1) EA004145B1 (et)
EE (1) EE04581B1 (et)
ES (1) ES2285841T3 (et)
HU (1) HUP0202048A3 (et)
NO (1) NO20005883L (et)
NZ (1) NZ508317A (et)
PL (1) PL345946A1 (et)
PT (1) PT1079843E (et)
SG (1) SG117434A1 (et)
SI (1) SI1079843T1 (et)
TR (1) TR200003432T2 (et)
WO (1) WO1999061040A2 (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
JP4975922B2 (ja) * 1999-09-14 2012-07-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
WO2001066140A1 (en) * 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
WO2004041846A2 (en) * 2002-11-01 2004-05-21 Boys Town National Research Hospital INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
EP2841579B1 (en) 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
US20230374141A1 (en) * 2020-10-05 2023-11-23 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
EP4431098A4 (en) * 2021-11-12 2025-10-08 Ube Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALPORT SYNDROME
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
WO1999061040A9 (en) 2001-02-01
SI1079843T1 (sl) 2007-10-31
NZ508317A (en) 2004-01-30
WO1999061040A3 (en) 2000-01-27
PL345946A1 (en) 2002-01-14
EA200001092A1 (ru) 2001-06-25
BR9911067A (pt) 2001-02-06
DK1079843T3 (da) 2007-07-30
CA2329757A1 (en) 1999-12-02
CA2329757C (en) 2013-11-19
NO20005883D0 (no) 2000-11-21
CN1187084C (zh) 2005-02-02
CZ296262B6 (cs) 2006-02-15
PT1079843E (pt) 2007-06-26
ATE359804T1 (de) 2007-05-15
TR200003432T2 (tr) 2001-03-21
ES2285841T3 (es) 2007-11-16
EP1079843A2 (en) 2001-03-07
SG117434A1 (en) 2005-12-29
CZ20004358A3 (cs) 2002-01-16
DE69935853T2 (de) 2008-01-10
EP1079843B1 (en) 2007-04-18
NO20005883L (no) 2001-01-17
DE69935853D1 (de) 2007-05-31
HUP0202048A3 (en) 2006-11-28
CN1310625A (zh) 2001-08-29
HUP0202048A2 (en) 2002-10-28
WO1999061040A2 (en) 1999-12-02
JP2002516287A (ja) 2002-06-04
EA004145B1 (ru) 2004-02-26
EE200000685A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
EE200000685A (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
NO20010446L (no) Substituert anilidforbindelser og metoder
AR049829A1 (es) Procedimiento y composiciones utiles para prevenir y/o tratar las pieles sensibles y/o secas
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
ATE234812T1 (de) Integrin antagonisten
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
BRPI0414724A (pt) combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit
TR200200278T2 (tr) Kalsilitik bileşimler
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
DE60021350D1 (de) Mmp-hemmer bei bindegewebserweichung
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
DK0841937T4 (da) Anvendelse af betaglycan til reduktion af ardannelse
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090519